Aura Biosciences’ (AURA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Aura Biosciences (NASDAQ:AURA) in a research note published on Thursday,Benzinga reports. The firm currently has a $22.00 price target on the stock.

A number of other research analysts have also recently commented on AURA. Evercore ISI raised Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. JMP Securities increased their price target on Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a research note on Friday, September 13th. BTIG Research boosted their price target on Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, October 18th. Cowen reissued a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. Finally, Scotiabank lifted their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a report on Friday, October 18th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $23.00.

Aura Biosciences Stock Down 5.0 %

NASDAQ AURA opened at $9.47 on Thursday. Aura Biosciences has a 52 week low of $6.63 and a 52 week high of $12.38. The company has a market capitalization of $473.04 million, a P/E ratio of -5.47 and a beta of 0.33. The stock’s 50-day moving average price is $9.82 and its 200-day moving average price is $8.53.

Aura Biosciences (NASDAQ:AURA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.02. Research analysts anticipate that Aura Biosciences will post -1.7 EPS for the current year.

Insiders Place Their Bets

In other news, insider Los Pinos Elisabet De sold 9,200 shares of the business’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $10.74, for a total transaction of $98,808.00. Following the completion of the sale, the insider now owns 320,647 shares in the company, valued at approximately $3,443,748.78. The trade was a 2.79 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Julie B. Feder sold 25,131 shares of the stock in a transaction on Friday, October 18th. The shares were sold at an average price of $12.03, for a total value of $302,325.93. Following the completion of the sale, the chief financial officer now owns 134,276 shares of the company’s stock, valued at approximately $1,615,340.28. This represents a 15.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 67,259 shares of company stock worth $780,699. 5.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Aura Biosciences

Large investors have recently added to or reduced their stakes in the stock. American Century Companies Inc. bought a new position in Aura Biosciences during the second quarter valued at about $119,000. American International Group Inc. grew its holdings in Aura Biosciences by 27.4% in the 1st quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after buying an additional 3,782 shares during the last quarter. Virtu Financial LLC acquired a new stake in Aura Biosciences in the 1st quarter worth $144,000. SG Americas Securities LLC acquired a new stake in Aura Biosciences during the third quarter worth about $169,000. Finally, Barclays PLC increased its stake in Aura Biosciences by 256.5% during the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock valued at $544,000 after acquiring an additional 43,897 shares during the period. 96.75% of the stock is owned by institutional investors and hedge funds.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.